Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| RYCEF | -0.78% | 14.18 | $ | |
| NGG | 0.65% | 70.95 | $ | |
| RELX | -0.49% | 47.555 | $ | |
| GSK | 0.21% | 39.725 | $ | |
| AZN | -0.03% | 79.64 | $ | |
| SCS | 0.88% | 16.535 | $ | |
| RIO | -0.73% | 61.88 | $ | |
| BTI | -1.1% | 57.17 | $ | |
| RBGPF | 0% | 75.55 | $ | |
| VOD | -0.27% | 11.838 | $ | |
| CMSC | 0.16% | 23.839 | $ | |
| BCC | 0.19% | 90.15 | $ | |
| BCE | -0.42% | 25.115 | $ | |
| JRI | -0.37% | 13.38 | $ | |
| CMSD | -0.44% | 23.915 | $ | |
| BP | -1.64% | 34.405 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
P.Venegas--GBA
